{"id":92170,"date":"2025-10-15T11:29:12","date_gmt":"2025-10-15T09:29:12","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=92170"},"modified":"2025-10-15T11:29:12","modified_gmt":"2025-10-15T09:29:12","slug":"andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/","title":{"rendered":"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline"},"content":{"rendered":"<p style=\"font-weight: 400;\">Andera Partners, a leading European private equity player, today announced that it participated in the \u20ac308 million (USD 361 million) Series C financing of its portfolio company Tubulis, underscoring Andera\u2019s continued support of the company\u2019s growth and clinical development progress. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C in addition to Andera Partners include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gr\u00fcnderfonds (HTGF), OCCIDENT, and Seventure Partners.<\/p>\n<p style=\"font-weight: 400;\">The proceeds from the Series C financing will be used to expand the clinical development of TUB-040, Tubulis\u2019 lead ADC candidate, into earlier lines of therapy and additional tumor indications. TUB-040 targets NaPi2b, an antigen that is overexpressed in ovarian cancer and lung adenocarcinomas. TUB-040 is currently being evaluated in a Phase I\/IIa study (NAPISTAR1-01, <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06303505?tab=results\">NCT06303505<\/a>) in patients with platinum-resistant ovarian cancer (PROC) as well as relapsed or refractory non-small cell lung cancer and was granted <a href=\"https:\/\/tubulis.com\/news\/tubulis-receives-fda-fast-track-designation-for-antibody-drug-conjugate-candidate-tub-040-in-platinum-resistant-ovarian-cancer\/\">Fast Track designation<\/a> by the U.S. FDA in June 2024. The capital will also advance Tubulis\u2019 pipeline, including the clinical-stage ADC candidate TUB-030, several preclinical programs, and expand its proprietary ADC platform technologies to bring ADCs into novel applications.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: 400;\">\u201c<em>This landmark financing round reflects the deep conviction these global healthcare investors have in Tubulis and the disruptive potential of our ADC platforms<\/em>,\u201d said <strong>Dr. Dominik Schumacher, CEO and Co-founder of Tubulis<\/strong>. \u201c<em>With TUB-040 progressing in the clinic and first data to be shared in a late-breaking oral presentation at ESMO, we are ready to expand into earlier treatment lines, while continuing to innovate across our pipeline and technology platforms. The new funding empowers us to execute on our vision of creating truly differentiated antibody-drug conjugates that are tailored to the biology of solid tumors and can deliver superior therapeutic value to patients<\/em>.\u201d<\/p>\n<p style=\"font-weight: 400;\"><strong>Sofia Ioannidou, PhD, Partner at Andera Partners<\/strong>, added: \u201c<em>Already in 2022, we were convinced of Tubulis\u2019 talented team, its differentiated technology platforms, and its promising ADC candidates. We led the Series B round at a critical stage of the company\u2019s development, contributing to the foundations for the fantastic progress accomplished by Tubulis since then. The company is now at clinical stage on the cusp of delivering valuable results for patients. We are proud to see our portfolio company attracting a top-tier syndicate of investors in the largest ever Series C for a European biotechnology company<\/em>.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners, a leading European private equity player, today announced that it participated in the \u20ac308 million (USD 361 million) Series C financing of its portfolio company Tubulis, underscoring Andera\u2019s continued support of the company\u2019s growth and clinical development progress. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-92170","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners, a leading European private equity player, today announced that it participated in the \u20ac308 million (USD 361 million) Series C financing of its portfolio company Tubulis, underscoring Andera\u2019s continued support of the company\u2019s growth and clinical development progress. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T09:29:12+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline\",\"datePublished\":\"2025-10-15T09:29:12+00:00\",\"dateModified\":\"2025-10-15T09:29:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\"},\"wordCount\":432,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\",\"name\":\"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2025-10-15T09:29:12+00:00\",\"dateModified\":\"2025-10-15T09:29:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline - ANDERA PARTNERS","og_description":"Andera Partners, a leading European private equity player, today announced that it participated in the \u20ac308 million (USD 361 million) Series C financing of its portfolio company Tubulis, underscoring Andera\u2019s continued support of the company\u2019s growth and clinical development progress. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2025-10-15T09:29:12+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline","datePublished":"2025-10-15T09:29:12+00:00","dateModified":"2025-10-15T09:29:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/"},"wordCount":432,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/","name":"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2025-10-15T09:29:12+00:00","dateModified":"2025-10-15T09:29:12+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-reinvests-in-tubulis-e308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-040-and-expand-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera Partners Reinvests in Tubulis\u2019 \u20ac308 million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=92170"}],"version-history":[{"count":1,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92170\/revisions"}],"predecessor-version":[{"id":92171,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/92170\/revisions\/92171"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=92170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=92170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}